Affymetrix will spend the $90 million it won from its settlement with Illumina on R&D projects and acquisitions, according to a company official.
 
The settlement ends more than three years of litigation between the companies, though patent re-examinations of Affy IP filed by Illumina will proceed and the possibility of future litigation between the array vendors exists. 
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.